Literature DB >> 22440989

Treatment with 50,000 IU vitamin D₂ every other week and effect on serum 25-hydroxyvitamin D₂, 25-hydroxyvitamin D₃, and total 25-hydroxyvitamin D in a clinical setting.

Emily T W Demetriou1, Thomas G Travison, Michael F Holick.   

Abstract

OBJECTIVE: To examine the effect of 50,000 IU-vitamin D₂ supplementation in a clinical setting on serum total 25-hydroxyvitamin D (25[OH]D), 25-hydroxyvitamin D₂ (25[OH]D₂), and 25-hydroxyvitamin D3 (25[OH]D₃).
METHODS: This retrospective cohort study was performed in an urban tertiary referral hospital in Boston, Massachusetts. Patients who had been prescribed 50,000 IU vitamin D₂ repletion and maintenance programs were identified through a search of our electronic medical record. Baseline and follow-up total serum 25(OH)D, 25(OH)D₂, and 25(OH)D₃ levels were compared.
RESULTS: We examined the medical records of 48 patients who had been prescribed 50,000 IU vitamin D₂ in our clinic. Mean ± standard deviation baseline total 25(OH)D was 31.0 ± 10.6 ng/mL and rose to 48.3 ± 13.4 ng/mL after treatment (P<.001). 25(OH)D₂ increased from 4.2 ± 4.3 ng/mL to 34.6 ± 12.3 ng/mL after treatment (P<.001), for an average of 158 days (range, 35-735 days). Serum 25(OH)D₃ decreased from 26.8 ± 10.8 ng/mL to 13.7 ± 7.9 ng/mL (P<.001).
CONCLUSIONS: Fifty thousand IU vitamin D₂ repletion and maintenance therapy substantially increases total 25(OH)D and 25(OH)D₂ despite a decrease in serum 25(OH)D₃. This treatment program is an appropriate and effective strategy to treat and prevent vitamin D deficiency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22440989     DOI: 10.4158/EP11268.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  17 in total

1.  Vitamin D for health: a global perspective.

Authors:  Arash Hossein-nezhad; Michael F Holick
Journal:  Mayo Clin Proc       Date:  2013-06-18       Impact factor: 7.616

Review 2.  The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention.

Authors:  Michael F Holick
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

3.  Higher 25(OH)D2 is associated with lower 25(OH)D3 and 1,25(OH)2D3.

Authors:  Christine M Swanson; Carrie M Nielson; Smriti Shrestha; Christine G Lee; Elizabeth Barrett-Connor; Ivo Jans; Jane A Cauley; Steven Boonen; Roger Bouillon; Dirk Vanderschueren; Eric S Orwoll
Journal:  J Clin Endocrinol Metab       Date:  2014-05-14       Impact factor: 5.958

Review 4.  Emphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilities.

Authors:  William B Grant; Sunil J Wimalawansa; Michael F Holick; John J Cannell; Pawel Pludowski; Joan M Lappe; Mary Pittaway; Philip May
Journal:  Nutrients       Date:  2015-02-27       Impact factor: 5.717

Review 5.  Factors Affecting 25-Hydroxyvitamin D Concentration in Response to Vitamin D Supplementation.

Authors:  Hajar Mazahery; Pamela R von Hurst
Journal:  Nutrients       Date:  2015-06-25       Impact factor: 5.717

6.  Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation.

Authors:  Hataikarn Nimitphong; Sunee Saetung; Suwannee Chanprasertyotin; La-Or Chailurkit; Boonsong Ongphiphadhanakul
Journal:  Nutr J       Date:  2013-04-04       Impact factor: 3.271

7.  Bronchoalveolar Lavage and Plasma Cathelicidin Response to 25-Hydroxy Vitamin D Supplementation: A Pilot Study.

Authors:  Emily C Sanders; Robert M Burkes; Jason R Mock; Todd T Brown; Robert A Wise; Nadia N Hansel; Mark C Liu; M Bradley Drummond
Journal:  Chronic Obstr Pulm Dis       Date:  2021-07-28

8.  Analysis of 25(OH)D serum concentrations of hospitalized elderly patients in the Shanghai area.

Authors:  Xudong Mao; Hongchao Zheng; Zhiwen Liu; Yan Wu; Risu Na; Chunping Wang; Xulei Zheng; Jing Gao; Liming Wu; Xiaohong Shi; Cong Liu; Hongguang Sheng
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

9.  Photobiology of vitamin D in mushrooms and its bioavailability in humans.

Authors:  Raphael-John H Keegan; Zhiren Lu; Jaimee M Bogusz; Jennifer E Williams; Michael F Holick
Journal:  Dermatoendocrinol       Date:  2013-01-01

10.  25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype.

Authors:  K S Jones; S Assar; D Harnpanich; R Bouillon; D Lambrechts; A Prentice; I Schoenmakers
Journal:  J Clin Endocrinol Metab       Date:  2014-06-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.